Beyond LDL Lowering? Palm Tocotrienols in Cardiometabolic Dyslipidemia: Reconciling Conflicting Lipid Effects with Antioxidant, Anti-Inflammatory, and Vascular Actions—A Critical Review

Abstract

Palm-derived tocotrienols have attracted sustained interest as nutraceutical candidates for cardiometabolic disease because experimental studies suggest effects on cholesterol synthesis, oxidative stress, inflammation, endothelial biology, and metabolic signalling. However, the clinical evidence for conventional lipid lowering is substantially less consistent than mechanistic narratives often imply. This critical qualitative literature review examines the apparent discrepancy between biological plausibility and human clinical outcomes. Contemporary randomized evidence does not support a reproducible, clinically substantial reduction in low-density lipoprotein cholesterol, total cholesterol, or triglycerides across populations and formulations, although selected studies report improvements in high-density lipoprotein cholesterol, inflammatory biomarkers, oxidative stress, insulin resistance, or related metabolic endpoints. Interpretation is complicated by heterogeneity in tocotrienol isomers, palm tocotrienol-rich fraction composition, α-tocopherol content, formulation, dose, bioavailability, participant phenotype, background diet, concomitant pharmacotherapy, and outcome selection. We therefore propose a “lipid-centric versus pleiotropic” model. Under the lipid-centric model, current evidence is insufficient to position tocotrienols as alternatives to established LDL-lowering therapy.